New research on the blood lipid-lowering protein FGF21 shows how it redistributes fatty acids by two distinct mechanisms. The discovery could lead to improved pharmaceutical treatment for type 2 diabetes and other obesity-related diseases. This according to a new study published in the journal Cell Metabolism.
“The protein FGF21 is an exciting potential therapeutic agent for the treatment of cardiovascular diseases and type 2 diabetes. This study provides breakthrough understanding mode of action of the protein,” says Stefan K. Nilsson, assistant professor at the Department of Medical Biosciences at Umeå University, who took part in the study as visiting scientist at the University Medical Centre in Hamburg.
The research results, published in the journal Cell Metabolism, shows that a part of FGF21′s redistributing effect on fatty acids can be explained by the fat-splitting enzyme Lipoprotein lipase (LPL).
Image: Umeå University